Chemotherapy for Pancreatic Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take warfarin while on the trial. Other anticoagulants are allowed, and you should discuss your specific medications with the study team.
What data supports the effectiveness of the drug combination of capecitabine and temozolomide for pancreatic cancer?
Research shows that capecitabine has been effective in treating advanced gastric and colorectal cancers, and temozolomide has shown activity in treating other types of tumors like melanoma and glioma. However, in a study specifically for pancreatic cancer, temozolomide alone was not effective, but the combination of capecitabine and temozolomide showed promise in treating pancreatic endocrine carcinomas.12345
Is temozolomide generally safe for humans?
Temozolomide is generally well tolerated and safe, with common side effects like fatigue, nausea, and mild blood-related issues. However, it can sometimes cause serious blood problems, such as myelodysplastic syndrome (a bone marrow disorder) and aplastic anemia (a condition where the body stops producing enough new blood cells).678910
How does the drug temozolomide differ from other treatments for pancreatic cancer?
Temozolomide is unique because it is an oral chemotherapy drug that is rapidly absorbed and has been used in other cancers like melanoma and glioma. However, it has shown limited effectiveness in treating pancreatic cancer, with most patients experiencing disease progression within two months.23111213
Research Team
Heloisa P Soares
Principal Investigator
SWOG Cancer Research Network
Eligibility Criteria
This trial is for adults who've had surgery for high-risk, well-differentiated pancreatic neuroendocrine tumors. They must be able to swallow pills, have no other active cancers (with some exceptions), and not have received certain treatments post-surgery. A complete medical history and physical exam are required, along with specific blood count and chemistry levels.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive capecitabine and temozolomide orally for up to 4 cycles, each cycle lasting 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Capecitabine
- Temozolomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
SWOG Cancer Research Network
Lead Sponsor
Southwest Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator